e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
93.11
+2.78 (+3.08%)
Streaming Delayed Price
Updated: 12:09 PM EDT, Mar 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
346,326
Open
91.54
Bid (Size)
93.05 (200)
Ask (Size)
93.12 (100)
Prev. Close
90.33
Today's Range
91.17 - 93.28
52wk Range
53.56 - 112.29
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
March 29, 2026
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...
Via
StockStory
Topics
Artificial Intelligence
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026
From
Incyte
Via
Business Wire
Performance
YTD
-8.2%
-8.2%
1 Month
-6.9%
-6.9%
3 Month
-6.2%
-6.2%
6 Month
+11.0%
+11.0%
1 Year
+53.8%
+53.8%
More News
Read More
Incyte Announces Executive Leadership Appointments
March 25, 2026
From
Incyte
Via
Business Wire
2 Growth Stocks with Explosive Upside and 1 We Avoid
March 23, 2026
Via
StockStory
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals
↗
February 21, 2026
Via
Chartmill
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 20, 2026
From
Incyte
Via
Business Wire
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
March 16, 2026
Via
StockStory
2 Value Stocks to Consider Right Now and 1 We Ignore
March 13, 2026
Via
StockStory
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
March 11, 2026
Via
StockStory
Topics
Stocks
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer
↗
March 06, 2026
Via
Stocktwits
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
March 06, 2026
From
Incyte
Via
Business Wire
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
March 04, 2026
Via
StockStory
3 S&P 500 Stocks to Target This Week
February 23, 2026
Via
StockStory
Topics
Stocks
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
February 18, 2026
Via
StockStory
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
From
USA News Group
Via
GlobeNewswire
Incyte to Present at Upcoming Investor Conferences
February 17, 2026
From
Incyte
Via
Business Wire
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
February 17, 2026
Via
StockStory
Topics
Earnings
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via
Finterra
Topics
Economy
Intellectual Property
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow
February 11, 2026
Via
StockStory
What's going on in today's session: S&P500 movers
↗
February 10, 2026
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday.
↗
February 10, 2026
Via
Chartmill
Why Incyte (INCY) Stock Is Nosediving
February 10, 2026
Via
StockStory
Topics
Artificial Intelligence
Earnings
Which S&P500 stocks are gapping on Tuesday?
↗
February 10, 2026
Via
Chartmill
Frequently Asked Questions
Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 93.11
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 03/31/26 12:09 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 20.71B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 21B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.